ALPHARETTA, Ga.--(BUSINESS WIRE)--SANUWAVE Health, Inc. (OTCBB: SNWV), an emerging medical technology company focused on the development and commercialization of noninvasive, biological response activating devices in regenerative medicine, today reported it has received a major deficiency letter from the United States Food and Drug Administration (FDA) regarding the FDA’s review of the dermaPACE® Premarket Approval Application (PMA) for the treatment of diabetic foot ulcers.